These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18667743)

  • 21. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine.
    Saitoh T; Satoh H; Nobuhara M; Machii M; Tanaka T; Ohtani H; Saotome M; Urushida T; Katoh H; Hayashi H
    Heart Vessels; 2011 Sep; 26(5):465-72. PubMed ID: 21127883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery.
    Ristikankare A; Kuitunen T; Kuitunen A; Uotila L; Vento A; Suojaranta-Ylinen R; Salmenperä M; Pöyhiä R
    Br J Anaesth; 2006 Nov; 97(5):611-6. PubMed ID: 16914459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
    Fu N; Liang M; Yang S
    Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast-Induced Nephropathy: A Failure of Academic Clinical Science.
    Sandilands EA; Rees JMB; Raja K; Dhaun N; Morrison EE; Hickson K; Wraight J; Gray T; Briody L; Cameron S; Thompson AP; Johnston NR; Uren N; Goddard J; Treweeke A; Rushworth G; Webb DJ; Bateman DN; Norrie J; Megson IL; Eddleston M
    Clin Pharmacol Ther; 2022 Jun; 111(6):1222-1238. PubMed ID: 35098531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report.
    Kim SM; Cha RH; Lee JP; Kim DK; Oh KH; Joo KW; Lim CS; Kim S; Kim YS
    Am J Kidney Dis; 2010 Jun; 55(6):1018-25. PubMed ID: 20097462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable.
    Hoffmann U; Fischereder M; Krüger B; Drobnik W; Krämer BK
    J Am Soc Nephrol; 2004 Feb; 15(2):407-10. PubMed ID: 14747387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization.
    Kato K; Sato N; Yamamoto T; Iwasaki YK; Tanaka K; Mizuno K
    Circ J; 2008 Sep; 72(9):1499-505. PubMed ID: 18724030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
    Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of cystatin C and serum creatinine for the diagnosis of contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography at an oncology centre.
    Fortalesa Melo JI; Chojniak R; Costa Silva DH; Oliveira Junior JC; Vieira Bitencourt AG; Holanda Silva D; Guimarães MD; Silva HC; Dias DG; Rodrigues WC; Brancucci EL; Cruz BM; Schiavon BN; Argenton JL; Camporini MA; Zocchio A
    PLoS One; 2015; 10(5):e0122877. PubMed ID: 25961558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease.
    Alharazy SM; Kong N; Saidin R; Gafor AH; Maskon O; Mohd M; Zakaria SZ
    Angiology; 2014 May; 65(5):436-42. PubMed ID: 23580616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 20-Hour preprocedural hydration is not superior to 5-hour preprocedural hydration in the prevention of contrast-induced increases in serum creatinine and cystatin C.
    Torigoe K; Tamura A; Watanabe T; Kadota J
    Int J Cardiol; 2013 Sep; 167(5):2200-3. PubMed ID: 22717305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystatin C, but not urinary or serum NGAL, may be associated with contrast induced nephropathy after percutaneous coronary invasive procedures: A single center experience on a limited number of patients.
    Cecchi E; Avveduto G; D'Alfonso MG; Terreni A; Gelera E; Caldini A; Giglioli C
    Acta Med Acad; 2017 May; 46(1):34-43. PubMed ID: 28605926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.